Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Gyongyos – page 4

223 clinical trials in Gyongyos, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gyongyos at a glance
223
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

223 trials in Gyongyos

Open in trial search

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Betovumeline
  • Sponsor:Maplight Therapeutics Inc.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study of Maridebart Cafraglutide for Adults with Obstructive Sleep Apnea and Overweight or Obesity Who Use Positive Airway Pressure Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study of the effectiveness and safety of alpha-lipoic acid and benfotiamine for the treatment of symptoms in patients with diabetic neuropathy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benfotiamine
  • Sponsor:Woerwag Pharma GmbH & Co. KG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Gyongyos

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on innovative treatments for non-small cell lung cancer (NSCLC) and chronic respiratory conditions, with multiple trials evaluating new immunotherapy combinations and targeted therapies.

  • Advanced NSCLC Treatment Studies
  • COPD Management Research
  • Idiopathic Pulmonary Fibrosis Studies

Several trials are exploring combination therapies to improve patient outcomes in advanced stages of lung cancer.

02 Autoimmune Conditions

Comprehensive studies on inflammatory and autoimmune disorders, including psoriasis and inflammatory bowel diseases, testing novel therapeutic approaches.

  • Plaque Psoriasis Treatments
  • Ulcerative Colitis Therapies
  • Crohn's Disease Management

Multiple trials are evaluating new biological therapies for moderate to severe cases of these conditions.

03 Cardiovascular Research

Innovative studies targeting heart failure prevention and cardiovascular disease management, with a focus on reducing major adverse cardiac events.

  • Heart Failure Prevention
  • Atherosclerotic Disease
  • Cardiovascular Risk Management

Research includes novel therapeutic combinations and preventive strategies for high-risk patients.

04 Neurological Disorders

Clinical research focusing on Alzheimer's Disease and associated conditions, particularly investigating treatments for psychosis symptoms.

  • Alzheimer's-Related Psychosis
  • Cognitive Function Studies

Trials are evaluating new therapeutic approaches for managing neuropsychiatric symptoms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.